Immunotherapy for tuberculosis: emerging modalities, cross-disciplinary innovations, and roadmaps for drug-resistant
Junchi Xu1,2, JunHeng Shen3, Sufang Chen1,2
1Department of clinical laboratory, The Affiliated Infectious Diseases Hospital, Suzhou Medical College of Soochow University, Suzhou, Jiangsu, China.
Rationale:
The emergence of multidrug-resistant tuberculosis (MDR-TB) and limitations of current antibiotic therapies highlight the urgent need for novel treatment strategies. While immunotherapy has revolutionized cancer treatment, its potential in TB remains underexplored, with existing reviews focusing narrowly on vaccines and phage therapy. A comprehensive synthesis of TB immunotherapy advancements is critical to guide clinical translation.
Content:
Tuberculosis (TB) has been recognized as one of the earliest diseases treated with immunotherapy. The BCG vaccine played a crucial role in controlling TB epidemics for a long period. However, progress in TB immunotherapy stagnated due to the attenuation of BCG strains and the long-standing neglect in TB immunology research. In recent years, advances in TB and immunology research, including novel immunological theories such as trained immunity, alongside breakthroughs in various immunotherapies for cancer treatment, have provided new perspectives for TB treatment. This review summarizes the immune response to TB, including roles of macrophages, T cells, and nonclassical immune cells. It evaluates progress in cell therapy, antibody therapy, microbial therapy, vaccines, and cytokine therapy. Clinical trials, mechanisms, and challenges (e.g., immune exhaustion, antigen heterogeneity) of TB immunotherapy are analyzed, drawing parallels with cancer immunotherapy.
Conclusions:
Immunotherapy offers multifaceted strategies to overcome Mtb drug resistance and reduce side effects. Key directions include identifying novel antigens, optimizing immune checkpoint modulation, and combining therapies. Advances in single-cell sequencing and bioengineering will accelerate development, making immunotherapy a promising adjunct to conventional TB treatment.
More Related Videos
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Tumor Immunotherapy
Microorganisms in Medicine and Therapeutics
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Therapeutic Drug Monitoring: Affecting Factors


